By Ethan Covey
A vaccine for cytomegalovirus (CMV), a common virus linked to high rates of birth defects, is entering phase 3 clinical trials.
Moderna is evaluating the safety and efficacy of a messenger RNA CMV vaccine (mRNA-1647) against primary CMV infection in women who are between 16 and 40 years of age in a study known as CMVictory.
According to the National CMV Foundation, CMV is the most common viral infection and leading cause nongenetic cause of hearing loss in infants who are born in